Cannabidivarin - GW Pharmaceuticals

Drug Profile

Cannabidivarin - GW Pharmaceuticals

Alternative Names: CBDV; CBDV - GW Pharmaceuticals; GWP-42006

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Charite - Universitatsmedizin Berlin; GW Pharmaceuticals
  • Class Antiepileptic drugs; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Partial epilepsies
  • Phase I Epilepsy; Pervasive child development disorders

Most Recent Events

  • 21 Feb 2018 Preliminary top-line efficacy and adverse events data from a phase II trial in Partial epilepsies released by Greenwich Biosciences
  • 04 Dec 2017 An investigator plans a placebo-controlled trial for Autistic disorder in the first half of 2018
  • 01 Sep 2017 GW Research completes a phase II trial in Partial epilepsies (Adjunctive treatment) in Italy, Czech Republic, Hungary, Poland, Spain, United Kingdom (PO) (NCT02365610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top